What Clinical Trials Can Teach Us about the Development of More Resilient AI for Cybersecurity
This addresses the problem of unreliable AI in cybersecurity for consumers and policymakers, but it is incremental as it adapts existing biomedical frameworks.
The paper tackles the lack of transparency and efficacy in AI-based cybersecurity tools by proposing a model inspired by clinical trials, aiming to improve resilience and guide future development.
Policy-mandated, rigorously administered scientific testing is needed to provide transparency into the efficacy of artificial intelligence-based (AI-based) cyber defense tools for consumers and to prioritize future research and development. In this article, we propose a model that is informed by our experience, urged forward by massive scale cyberattacks, and inspired by parallel developments in the biomedical field and the unprecedentedly fast development of new vaccines to combat global pathogens.